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LETTERS TO THE EDITOR
Therapy of Fabry disease
To the Editor: Referring to a Nephrology Forum by
Siamopoulos et al [1] entitled “Fabry disease: Kidney in-
volvement and enzyme replacement therapy” in a recent
issue of Kidney International, we have to comment on
two issues:
(1) Dr. Siamopoulos claims, “The availability of en-
zyme replacement therapy remarkably improves out-
come of patients with Fabry disease.”
This contention has not been proven formally by ran-
domized controlled trials. The primary end points of two
clinical trials showed disappearance of microvascular en-
dothelial Gb3 deposits in renal biopsies [2] and decrease
of neuropathic pain [3] after several weeks of enzyme
replacement therapy. All other outcomes of the previ-
ously mentioned trials, such as decrease of resting global
cerebral blood flow [4], clearance of deposits in endomy-
ocardium and skin, quality of life, pain score [2], esti-
mated glomerular filtration rate, Gb3 plasma levels, and
cardiac conduction [3] have only been secondary end
points, and thus, remain hypothesis generating. Other un-
controlled studies suggested a decrease of left ventricu-
lar hypertrophy [5], a reduction in QRS duration [6], an
improvement in patients’ New York Heart Association
(NYHA) functional heart failure class [6], and an im-
provement of sweat function [7]. However, the design of
these trials precludes valid conclusion on the efficacy of
enzyme replacement therapy in Fabry disease.
(2) Dr. Siamopoulos also mentions “most heterozy-
gote women remain asymptomatic and have a normal
life span, only some expressing a few minor manifesta-
tions. Cardiac and renal manifestations in heterozygous
women are usually lacking.”
By way of contrast, two studies report that almost all
females show multisystem involvement [8] and a decrease
in life expectancy of about 15 years compared to the gen-
eral population [9].
Although enzyme replacement therapy [2, 3] may
hopefully reduce disease burden of female and male
patients with Fabry disease, the improvement of many
clinical end points still remains to be established. In the
meantime, the clinical observations obtained in patients
under enzyme replacement therapy should be considered
more critically.
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Reply from the Author
As far as evidence-based medicine is concerned, I agree
with Dr. Kleinert et al that the “outcomes” of patients
with Fabry disease after enzyme replacement therapy
(ERT) have not yet been confirmed in large randomized
controlled trials. However, in my opinion, the rarity of this
disorder should encourage us to take into consideration
results from several independent investigators referring
to a relatively small number of treated patients (as refer-
enced by Dr. Kleinert et al), or even case reports [1], and
the case of the first patient discussed in the Nephrology
Forum, which clearly prove the clinical benefit of ERT.
It is suggested that ERT should be initiated in all pa-
tients with Fabry disease [2], and treatment should ideally
begin as soon as clinical signs and symptoms are observed.
As I concluded in my discussion, I tried to raise aware-
ness of the nephrologists in diagnosing the disease early.
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